AARDEX Group

Successful MEMS Intervention in HIV Pre-Exposure Prophylaxis

mems_img
NOV-2017 : Incredible, one year has already passed since we presented one of the most

NOV-2017 : Incredible, one year has already passed since we presented one of the most interesting projects in medication adherence monitoring. MEMS® (Medication Event Monitoring System) were shown to be a useful tool to increase adherence to PrEP medication in large multi-country projects run in challenging low resource settings.

We walk the talk
The MEMS® (Medication Event Monitoring System) are being used as a tool to measure adherence and guide an intervention in subjects on PrEP medication (Pre-Exposure Prophylaxis for HIV) in a multi-country low resource setting medical practice program.

The program is currently initiated in 4 centers located in the vicinity of Dakar, Senegal (N=161) and 5 centers in Nairobi and in remote locations by the Victoria Lake, Kenya (N=786). The dosing history data recorded by the MEMS® is used for individual feedback, at point of care, in a focused discussion between the health service providers and the subjects. After receiving the MEMS® based intervention, the likelihood of taking the medication as prescribed increased by 13% in the targeted population(1).

These preliminary results are encouraging and suggest the feasibility and effectiveness of measurement-guided adherence-enhancing intervention based on MEMS monitoring and feedback in resource-limited settings.

Reach out to us a MEMS@aardexgroup.com to receive more information about the use of the MEMS® (Medication Event Monitoring System).

Best Regards,

The MEMS® team


(1) Espacomp 2016 – Successful measurement-guided Adherence-enhancing intervention in HIV pre-exposure prophylaxis (PrEP) in low-resource settings – Results from interim analysis

Share This Post

You may also like...

Breaking News

Dose reduction’s role in tackling Pharma 2.0’s profitability problem

The economic model that has underpinned the development of drug products for decades is currently under siege. Faced on one side with mounting pressure from payers to address affordability issues, pharmaceutical companies are facing ever more stringent regulatory requirements alongside